COMPASS Pathways Granted Patent Covering Use of Its Psilocybin Formulation in Addressing Treatment-resistant Depression
LONDON, January 13, 2020 /PRNewswire=KYODO JBN/--
COMPASS Pathways, a mental health care company, announced today that it has been granted
US Patent No 10,519,175, relating to methods of treating drug-resistant depression with
a psilocybin formulation, by the US Patent and Trademark Office. The patent covers the use
of COMPASS's synthesised investigational psilocybin formulation, COMP360, in a psilocybin
therapy protocol for patients with treatment-resistant depression. Psilocybin is an active
ingredient in so-called 'magic mushrooms'.
Last month, COMPASS reported [https://www.prnewswire.com/news-releases/compass-pathways-and-kings-college-london-announce-results-from-psilocybin-study-in-healthy-volunteers-300973347.html ] that COMP360 was well tolerated when administered to healthy
adult volunteers with support from specially trained therapists in a randomised
placebo-controlled trial. COMPASS is currently running a phase IIb clinical trial
[https://clinicaltrials.gov/ct2/show/NCT03775200 ] of COMP360 in treatment-resistant
depression. This trial is recruiting 216 patients from across Europe and North America
who suffer with depression that hasn't responded to established medications, and will be
the largest clinical trial of a psilocybin formulation to date. In 2018, COMPASS received FDA
"Breakthrough Therapy" designation [https://www.prnewswire.com/news-releases/compass-pathways-receives-fda-breakthrough-therapy-designation-for-psilocybin-therapy-for-treatment-resistant-depression-834088100.html ] for its programme of psilocybin therapy for treatment-resistant depression.
George Goldsmith, CEO and Co-founder, COMPASS Pathways, said, "Too many people are
suffering with treatment resistant depression. We are committed to developing innovations,
such as psilocybin therapy, to address this rapidly growing problem. Patents help ensure
sustainable funding to conduct the highest quality clinical research to bring the best new
therapies to patients who urgently need them. If this research demonstrates psilocybin
therapy is a safe and effective option for patients, we will price it responsibly with the goal
of making it as affordable and accessible as possible."
About COMPASS Pathways
COMPASS Pathways is a mental health care company dedicated to accelerating
patient access to evidence-based innovation in mental health. We are developing
psilocybin therapy through a late-stage clinical trial in Europe and North America
for patients with treatment-resistant depression. COMP360 is an investigational
psilocybin formulation developed and produced by COMPASS Pathways.
Tracy Cheung, email@example.com, +44 7966 309024
Amy Lawrence, firstname.lastname@example.org, +44 7813 777919
SOURCE: COMPASS Pathways